Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharma, Tavanta Therapeutics, Candel Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate Cancer Market.

The Metastatic Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Metastatic Prostate Cancer Pipeline Report: https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Metastatic Prostate Cancer treatment therapies with a considerable amount of success over the years.
• Metastatic Prostate Cancer companies working in the treatment market are Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharmaceuticals, Tavanta Therapeutics, Candel Therapeutics, Jiangsu Hengrui Pharmaceuticals, and others, are developing therapies for the Metastatic Prostate Cancer treatment
• Emerging Metastatic Prostate Cancer therapies in the different phases of clinical trials are- 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others are expected to have a significant impact on the Metastatic Prostate Cancer market in the coming years.
• In February 2025, Halda Therapeutics, a clinical-stage biotech firm pioneering a new category of cancer treatments known as RIPTACTM (Regulated Induced Proximity Targeting Chimeras) therapeutics, has announced that the first patient has been dosed in its inaugural Phase 1/2 human clinical trial (NCT06800313). The study aims to evaluate the safety and tolerability of its investigational therapy, HLD-0915, in patients with metastatic castration-resistant prostate cancer (mCRPC).
• In February 2025, Israeli pharma company RedHill Biopharma has initiated a placebo-controlled Phase II clinical trial to investigate the combination of opaganib and darolutamide for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). The trial, which includes 80 male patients, is designed to determine if opaganib can enhance the efficacy of standard androgen receptor pathway inhibition (ARPI) therapies.
• In February 2025, Halda Therapeutics, a clinical-stage biotech firm advancing a novel class of cancer treatments called RIPTACTM (Regulated Induced Proximity Targeting Chimeras), has announced that the first patient has been dosed in its Phase 1/2 clinical trial (NCT06800313). The study aims to evaluate the safety and tolerability of HLD-0915 in patients with metastatic castration-resistant prostate cancer (mCRPC).
• In December 2024, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on creating multimodal biological immunotherapies for cancer, has announced findings from a multicenter Phase 3 clinical trial evaluating the effectiveness of its viral immunotherapy, CAN-2409, in patients with localized prostate cancer.
• In November 2024, The US Food and Drug Administration (FDA) has accepted Bayer's supplemental new drug application (sNDA) for its oral androgen receptor inhibitor (ARi), Nubeqa (darolutamide), for treating metastatic hormone-sensitive prostate cancer (mHSPC). The therapy is used in combination with androgen deprivation therapy (ADT). The sNDA submission is supported by positive findings from the Phase III ARANOTE trial, where the combination treatment achieved its primary endpoint by significantly improving radiological progression-free survival (rPFS).

Metastatic Prostate Cancer Overview
Metastatic prostate cancer is an advanced stage of prostate cancer in which cancer cells spread from the prostate gland to other parts of the body, such as the bones, lymph nodes, liver, or lungs. This occurs when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to form secondary tumors. Symptoms may include bone pain, difficulty urinating, fatigue, and weight loss. Treatment for metastatic prostate cancer focuses on slowing the cancer's progression, managing symptoms, and improving quality of life, using options like hormone therapy, chemotherapy, immunotherapy, and targeted therapies.

Get a Free Sample PDF Report to know more about Metastatic Prostate Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Metastatic Prostate Cancer Drugs Under Different Phases of Clinical Development Include:
• 177Lu-PSMA-I&T: Curium
• Opevesostat (MK-5684; ODM-208): Merck/ Orion
• Mevrometostat (PF-06821497): Pfizer
• TRUQAP (capivasertib, AZD5363): AstraZeneca
• 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
• TAVT-45 (abiraterone acetate): Tavanta Therapeutics
• Saruparib (AZD5305): AstraZeneca
• CAN-2409 (aglatimagene besadenovec): Candel Therapeutics
• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Metastatic Prostate Cancer Route of Administration
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Metastatic Prostate Cancer Molecule Type
Metastatic Prostate Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Metastatic Prostate Cancer Pipeline Therapeutics Assessment
• Metastatic Prostate Cancer Assessment by Product Type
• Metastatic Prostate Cancer By Stage and Product Type
• Metastatic Prostate Cancer Assessment by Route of Administration
• Metastatic Prostate Cancer By Stage and Route of Administration
• Metastatic Prostate Cancer Assessment by Molecule Type
• Metastatic Prostate Cancer by Stage and Molecule Type

DelveInsight's Metastatic Prostate Cancer Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Metastatic Prostate Cancer product details are provided in the report. Download the Metastatic Prostate Cancer pipeline report to learn more about the emerging Metastatic Prostate Cancer therapies
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Metastatic Prostate Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Prostate Cancer are - MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others.

Metastatic Prostate Cancer Pipeline Analysis:
The Metastatic Prostate Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
• Metastatic Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Prostate Cancer drugs and therapies
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Metastatic Prostate Cancer Pipeline Market Drivers
• Growing Incidence of Prostate Cancer, Innovative Therapeutic Developments, Government and Non-Profit Funding Support, Aging Population, are some of the important factors that are fueling the Metastatic Prostate Cancer Market.

Metastatic Prostate Cancer Pipeline Market Barriers
• However, High Cost of Drug Development, Complex Disease Mechanism, Regulatory Hurdles, Adverse Side Effects of Treatments, and other factors are creating obstacles in the Metastatic Prostate Cancer Market growth.

Scope of Metastatic Prostate Cancer Pipeline Drug Insight
• Coverage: Global
• Key Metastatic Prostate Cancer Companies: Curium, Merck/ Orion, Pfizer, AstraZeneca, Telix Pharmaceuticals, Tavanta Therapeutics, Candel Therapeutics, Jiangsu Hengrui Pharmaceuticals, and others
• Key Metastatic Prostate Cancer Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others
• Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
• Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers

Request for Sample PDF Report for Metastatic Prostate Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Metastatic Prostate Cancer Report Introduction
2. Metastatic Prostate Cancer Executive Summary
3. Metastatic Prostate Cancer Overview
4. Metastatic Prostate Cancer- Analytical Perspective In-depth Commercial Assessment
5. Metastatic Prostate Cancer Pipeline Therapeutics
6. Metastatic Prostate Cancer Late Stage Products (Phase II/III)
7. Metastatic Prostate Cancer Mid Stage Products (Phase II)
8. Metastatic Prostate Cancer Early Stage Products (Phase I)
9. Metastatic Prostate Cancer Preclinical Stage Products
10. Metastatic Prostate Cancer Therapeutics Assessment
11. Metastatic Prostate Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Metastatic Prostate Cancer Key Companies
14. Metastatic Prostate Cancer Key Products
15. Metastatic Prostate Cancer Unmet Needs
16 . Metastatic Prostate Cancer Market Drivers and Barriers
17. Metastatic Prostate Cancer Future Perspectives and Conclusion
18. Metastatic Prostate Cancer Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Metastatic Prostate Cancer Market https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Metastatic Prostate Cancer Epidemiology https://www.delveinsight.com/report-store/metastatic-prostate-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Metastatic Prostate Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.